The association between the expression of solute carrier
transporters and the prognosis of pancreatic cancer

J 2013

The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer

MOHELNIKOVA-DUCHONOVA, Beatrice, Veronika BRYNYCHOVA, Viktor HLAVAC, Matej KOCIK, Martin OLIVERIUS et. al.

Základní údaje

Originální název

The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer

Autoři

MOHELNIKOVA-DUCHONOVA, Beatrice (203 Česká republika), Veronika BRYNYCHOVA (203 Česká republika), Viktor HLAVAC (203 Česká republika), Matej KOCIK (203 Česká republika), Martin OLIVERIUS (203 Česká republika), Jan HLAVSA (203 Česká republika, garant, domácí), Eva HONSOVA (203 Česká republika), Jan MAZANEC (203 Česká republika, domácí), Zdeněk KALA (203 Česká republika, domácí), Bohuslav MELICHAR (203 Česká republika) a Pavel SOUCEK (203 Česká republika)

Vydání

CANCER CHEMOTHERAPY AND PHARMACOLOGY, NEW YORK, SPRINGER, 2013, 0344-5704

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.571

Kód RIV

RIV/00216224:14110/13:00071472

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s00280-013-2246-2

UT WoS

000323653600019

Klíčová slova anglicky

Pancreatic cancer; SLC transporters; Gene expression; Survival; KRAS

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 2. 2014 13:32, Soňa Böhmová

Anotace

V originále

The aim of this study was to investigate the prognostic significance of fourteen anticancer drug-relevant solute carrier transporters (SLCs) in pancreatic cancer in the context of clinical-pathological characteristics and the KRAS mutation status of tumors. Tumors and non-neoplastic pancreatic tissues were obtained from 32 histologically verified patients with pancreatic ductal adenocarcinoma. The transcript profile of SLCs was assessed using quantitative real-time PCR. KRAS mutations in exon 2 were assessed by high-resolution melting analysis and confirmed by sequencing. SLC22A3 and SLC22A18 were upregulated and SLC22A1, SLC22A2, SLC22A11, SLC28A1, SLC28A3 and SLC29A1 were downregulated when compared with non-neoplastic pancreatic tissues. Moreover, significantly lower levels of SLC22A1, SLC22A11 and SLC29A1 were found in tumors with angioinvasion. There was also a significantly higher transcript level of SLC28A1 in tumors with regional lymph nodes affected by metastasis. The study found that a high expression of SLC28A1 was significantly associated with poor overall survival in unselected patients. In contrast, a high expression of SLC22A3 or SLC29A3 was significantly associated with longer overall survival in patients treated with nucleoside analogs. Protein expression of SLC22A1, SLC22A3 and SLC29A3 in tumor tissues of patients with pancreatic carcinoma was observed by immunoblotting for the first time. Finally, SLC levels were not found to be associated with KRAS mutation status in exon 2. This study identified a number of associations of transcript levels of SLCs with prognosis of pancreatic cancer patients.

Citovat

MOHELNIKOVA-DUCHONOVA, Beatrice, Veronika BRYNYCHOVA, Viktor HLAVAC, Matej KOCIK, Martin OLIVERIUS, Jan HLAVSA, Eva HONSOVA, Jan MAZANEC, Zdeněk KALA, Bohuslav MELICHAR a Pavel SOUCEK. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. CANCER CHEMOTHERAPY AND PHARMACOLOGY. NEW YORK: SPRINGER, 2013, roč. 72, č. 3, s. 669-682. ISSN 0344-5704. Dostupné z: https://dx.doi.org/10.1007/s00280-013-2246-2.

@article{1161486,
   author = {MohelnikovaandDuchonova, Beatrice and Brynychova, Veronika and Hlavac, Viktor and Kocik, Matej and Oliverius, Martin and Hlavsa, Jan and Honsova, Eva and Mazanec, Jan and Kala, Zdeněk and Melichar, Bohuslav and Soucek, Pavel},
   article_location = {NEW YORK},
   article_number = {3},
   doi = {http://dx.doi.org/10.1007/s00280-013-2246-2},
   keywords = {Pancreatic cancer; SLC transporters; Gene expression; Survival; KRAS},
   language = {eng},
   issn = {0344-5704},
   journal = {CANCER CHEMOTHERAPY AND PHARMACOLOGY},
   title = {The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer},
   volume = {72},
   year = {2013}
}

TY  - JOUR
ID  - 1161486
AU  - Mohelnikova-Duchonova, Beatrice - Brynychova, Veronika - Hlavac, Viktor - Kocik, Matej - Oliverius, Martin - Hlavsa, Jan - Honsova, Eva - Mazanec, Jan - Kala, Zdeněk - Melichar, Bohuslav - Soucek, Pavel
PY  - 2013
TI  - The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer
JF  - CANCER CHEMOTHERAPY AND PHARMACOLOGY
VL  - 72
IS  - 3
SP  - 669-682
EP  - 669-682
PB  - SPRINGER
SN  - 03445704
KW  - Pancreatic cancer
KW  - SLC transporters
KW  - Gene expression
KW  - Survival
KW  - KRAS
N2  - The aim of this study was to investigate the prognostic significance of fourteen anticancer drug-relevant solute carrier transporters (SLCs) in pancreatic cancer in the context of clinical-pathological characteristics and the KRAS mutation status of tumors. Tumors and non-neoplastic pancreatic tissues were obtained from 32 histologically verified patients with pancreatic ductal adenocarcinoma. The transcript profile of SLCs was assessed using quantitative real-time PCR. KRAS mutations in exon 2 were assessed by high-resolution melting analysis and confirmed by sequencing. SLC22A3 and SLC22A18 were upregulated and SLC22A1, SLC22A2, SLC22A11, SLC28A1, SLC28A3 and SLC29A1 were downregulated when compared with non-neoplastic pancreatic tissues. Moreover, significantly lower levels of SLC22A1, SLC22A11 and SLC29A1 were found in tumors with angioinvasion. There was also a significantly higher transcript level of SLC28A1 in tumors with regional lymph nodes affected by metastasis. The study found that a high expression of SLC28A1 was significantly associated with poor overall survival in unselected patients. In contrast, a high expression of SLC22A3 or SLC29A3 was significantly associated with longer overall survival in patients treated with nucleoside analogs. Protein expression of SLC22A1, SLC22A3 and SLC29A3 in tumor tissues of patients with pancreatic carcinoma was observed by immunoblotting for the first time. Finally, SLC levels were not found to be associated with KRAS mutation status in exon 2. This study identified a number of associations of transcript levels of SLCs with prognosis of pancreatic cancer patients.
ER  -

MOHELNIKOVA-DUCHONOVA, Beatrice, Veronika BRYNYCHOVA, Viktor HLAVAC, Matej KOCIK, Martin OLIVERIUS, Jan HLAVSA, Eva HONSOVA, Jan MAZANEC, Zdeněk KALA, Bohuslav MELICHAR a Pavel SOUCEK. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. \textit{CANCER CHEMOTHERAPY AND PHARMACOLOGY}. NEW YORK: SPRINGER, 2013, roč.~72, č.~3, s.~669-682. ISSN~0344-5704. Dostupné z: https://dx.doi.org/10.1007/s00280-013-2246-2.

Podrobný výpis o publikaci